Tue, Sep 30, 2014, 3:30 AM EDT - U.S. Markets open in 6 hrs.

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • alazoner alazoner Jun 20, 2014 12:16 AM Flag

    6-12 month for final approval and launch--That is why breakthrough is a big deal

    Don't miss the boat.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 6-12 months is BIG problem. It is better to take the profit now and come back after 5 months. This stock went up more than 45%; if I will wait that long then those people who bought it at lower price will take their profits and this stock can go down + shorts are anticipating profit taking. They will capitalize the situation and bring this stock down more...I see this happening over and over. Well, that is only my analysis.

    • Arikayce joined the list!!

      Num Drug Name Sponsor Company Indication
      1 Daratumumab Genmab/Janssen Multiple

      Myeloma

      (MM)
      2 Ibrutinib Pharmacyclics Relapsed Or

      Refractory

      Mantle

      Cell

      Lymphoma (MCL)
      3 Ibrutinib Pharmacyclics Waldenstroms

      Macroglobulinemia
      4 Ibrutinib Pharmacyclics Chronic or Small

      Lymphocytic

      Leukemia

      (CLL/SLL)
      5 Kalydeco Vertex Pharmaceuticals Cystic Fibrosis
      6 Kalydeco + Lumacaftor (VX-809) Vertex Pharmaceuticals Cystic Fibrosis
      7 Lambrolizumab Merck Melanoma
      8 LDK378 Novartis ALK+

      Non-Small

      Cell Lung

      Cancer (NSCLC)
      9 Palbociclib Pfizer Breast Cancer
      10 SD-101 Scioderm Epidermolysis

      Bullosa
      11 3-drug regimen Bristol-Myers Squibb Hepatitis C
      12 3-drug combination AbbVie Hepatitis C
      13 Obinutuzumab Genentech Chronic

      Lymphocytic

      Leukemia

      (CLL)
      14 Sebelipase Alfa Synageva

      BioPharma
      Lysosomal

      Acid Lipase

      Deficiency
      15 Asfotase Alfa Alexion

      Pharmaceuticals
      Hypophosphatasia
      16 Serelaxin Novartis Acute Heart

      Failure

      (AHF)
      17 Drisapersen GlaxoSmithKline Duchenne

      Muscular

      Dystrophy
      18 Bimagrumab Novartis Sporadic

      Inclusion

      Body Myositis
      19 Sofosbuvir +Ledipasvir Gilead Sciences Hepatitis C
      20 Firdapse Catalyst

      Pharmaceutical

      Partners
      Lambert-Eaton

      Myasthenic

      Syndrome
      21 Entinostat Syndax Pharmaceuticals Metastatic

      ER+Breast

      Cancer
      22 Ofatumumab Genmab/GSK Chronic

      Lymphocytic

      Leukemia (CLL)
      23 Volasertib Boehringer

      Ingelheim
      Acute Myeloid

      Leukemia

      (AML)
      24 Alectinib Roche ALK+

      Non-Small

      Cell Lung

      Cancer

      (NSCLC)
      25 MK-5172/MK-8742 Merck Hepatitis C
      26 Cyclic Pyranopterin Monophosphate (cPMP) Alexion

      Pharmaceuticals
      Molybdenum

      Cofactor

      Deficiency

      (MoCD) Type A
      27 Andexanet Alfa Portola Pharmaceuticals Reversal of Factor

      Xa

      Inhibitor

      Anticoagulation
      28 Tafenoquine GSK/Medicines for Malaria Venture Plasmodium

      Vivax

      Malaria
      29 Idelalisib Gilead Sciences Relapsed

      Chronic Lymphocytic

      Leukemia
      30 Dabrafenib GSK Non-Small

      Cell Lung

      Cancer With

      BRAF Mutation
      31 Kalydeco + VX-661 Vertex Pharmaceuticals Cystic Fibrosis
      32 Eltrombopag GSK Severe

      Aplastic

      Anemia
      33 Sofosbuvir Gilead Sciences Hepatitis C
      34 Daclatasvir + Asunaprevir Bristol-Myers Squibb Hepatitis C
      35 Bivalent rLP2086 Vaccine Pfizer Meningococcal B

      Disease
      36 Bexsero Vaccine Novartis Meningococcal B

      Disease
      37 Mydicar Celladon Corporation Reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative
      38 AZD9291 AstraZeneca Metastatic EGFR T790M mutation-positive NSCLC
      39 Nivolumab Bristol-Myers Squibb Hodgkin Lymphoma
      40 Elotuzumab Bristol-Myers Squibb/AbbVie Multiple Myeloma
      41 CO-1686 Clovis Oncology 2nd Line EGFR Mutant NSCLC with T790M Mutation
      42 MPDL3280A (anti-PDL1) Genentech Urothelial Bladder Cancer (UBC)
      43 Arikayce Insmed Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

      Sentiment: Strong Buy

 
INSM
13.51+0.19(+1.43%)Sep 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
GoPro, Inc.
NasdaqGSMon, Sep 29, 2014 4:15 PM EDT
Cyber-Ark Software Ltd.
NasdaqGSMon, Sep 29, 2014 4:00 PM EDT